{{Drugbox
| drug_name = 
| IUPAC_name        = 1-Cyclopropyl-6-fluoro-7-[4-({2-fluoro-4-[(5''R'')-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenoxy}methyl)-4-hydroxypiperidin-1-yl]-4-oxo-1,4-dihydroquinolin-3-carboxylic acid
| image             = Cadazolid.svg
| alt               = 
| caption           = 
| width             = 250

<!-- Clinical data -->
| tradename         = 
| Drugs.com         = 
| MedlinePlus       = 
| pregnancy_AU      = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US      = <!-- A / B            / C / D / X -->
| pregnancy_category= 
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, CD Lic, CD POM, CD No Reg POM, CD (Benz) POM, CD (Anab) POM or CD Inv POM -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status      = Investigational
| routes_of_administration =

<!-- Pharmacokinetic data -->
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         =

<!-- Identifiers -->
| CAS_number        = 1025097-10-2

| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 2OEA2UN10Y


| ATCvet            = 
| ATC_prefix        = none
| ATC_suffix        = 
| PubChem           = 
| DrugBank          = 
| ChemSpiderID      = 30774277

<!-- Chemical data -->
| C=29 | H=29 | F=2 | N=3 | O=8
| molecular_weight  = 585.55 g/mol
| smiles            = OC(C1=CN(C2CC2)C3=C(C=C(F)C(N4CCC(COC5=C(F)C=C(N6C[C@H](CO)OC6=O)C=C5)(O)CC4)=C3)C1=O)=O
| StdInChI          = 1S/C29H29F2N3O8/c30-21-10-19-23(33(16-1-2-16)13-20(26(19)36)27(37)38)11-24(21)32-7-5-29(40,6-8-32)15-41-25-4-3-17(9-22(25)31)34-12-18(14-35)42-28(34)39/h3-4,9-11,13,16,18,35,40H,1-2,5-8,12,14-15H2,(H,37,38)/t18-/m1/s1
| StdInChIKey       = XWFCFMXQTBGXQW-GOSISDBHSA-N
}}

'''Cadazolid''' is an experimental [[antibacterial|antibiotic]] of the [[2-Oxazolidone|oxazolidinone]] class made by [[Actelion|Actelion Pharmaceuticals Ltd.]] which is effective against ''[[Clostridium difficile (bacteria)|Clostridium difficile]]'', a major cause of drug resistant [[diarrhea]] in the elderly.<ref name="www.internalmedicinenews.com">{{cite web |url=http://www.internalmedicinenews.com/index.php?id=2049&type=98&tx_ttnews%5Btt_news%5D=137097&cHash=da03e20e36 |title=Promising ''C. difficile'' Antibiotic in Pipeline |last1=Boschert |first1=Sherry |date=19 Sep 2012 |website=Internal Medicine News |publisher= International Medical News Group |accessdate=22 May 2013}}</ref> Current drug treatments for this infection involve orally delivered antibiotics, principally [[fidaxomicin]], [[metronidazole]] and [[vancomycin]]; the last two drugs are the  principal therapeutic agents in use, but fail in  approximately 20 to 45% of the cases. The drug is in Phase III trials.<ref name="www.internalmedicinenews.com"/> The drug works by inhibiting synthesis of proteins in the bacteria, thus inhibiting the production of toxins and the formation of spores.<ref name="Cadazolid">{{cite web|url=http://www1.actelion.com/en/scientists/development-pipeline/phase-2/cadazolid.page |title=Cadazolid |publisher=.actelion.com |date= |accessdate=2013-05-22}}</ref>

==Structure==
The [[chemical structure]] of cadazolid combines the [[pharmacophore]]s of oxazolidinone and [[fluoroquinolone]].<ref name="Cadazolid"/>

==Clinical trials==
In a study published in the journal ''Anaerobe'', cadazolid has been shown to be effective ''[[in vitro]]'' against 133 strains of ''Clostridium difficile'' all collected from [[Sweden]].<ref name="ScienceDirect">{{cite journal|url=http://www.sciencedirect.com/science/article/pii/S1075996413000231 |title=Anaerobe - In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden  |date=2013-02-26 |accessdate=2013-05-22 |doi=10.1016/j.anaerobe.2013.02.003 |volume=20 |journal=Anaerobe |pages=32â€“35}}</ref>

In phase I tests, sixty four male patients reacted favourably to cadazolid which primarily acted and remained in the [[colon (anatomy)|colon]] while displaying little toxicity even in regimes involving large doses.<ref name="www.internalmedicinenews.com"/>

== References ==
{{reflist}}

[[Category:Experimental drugs]]
[[Category:Fluoroquinolone antibiotics]]


{{antibiotic-stub}}